- Head of Next Generation Thematic
Skip to main content
- Funds
- Insights
- Capabilities
- About Us
- My Account
The views expressed are those of the authors at the time of writing. Other teams may hold different views and make different investment decisions. The value of your investment may become worth more or less than at the time of original investment. While any third-party data used is considered reliable, its accuracy is not guaranteed. For professional, institutional, or accredited investors only.
A variety of secular trends are spurring innovation and disruption in the global economy and creating what we believe are compelling thematic investment opportunities. In this series of articles, we take a close look at some of these trends, the breadth of the opportunity set and the related risks.
Here, we focus on medical innovation — how advances in science, tools and technologies are paving the way for treatments that are more effective, more precise and come with fewer side effects. Leveraging research insights from both our thematic team and our global industry health care experts, we specifically examine how two key areas of innovation — biotechnology (biotech) and medical technology (medtech) — are transforming the face of health care.
Resolving the root causes of diseases at a molecular level — By making use of cellular and biomolecular processes, the biotech industry has the potential to identify and treat the root causes of diseases.
Gene therapy — a form of treatment designed to introduce genetic material into cells to compensate for abnormal genes — is one example of this approach. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene in order to restore proper function.
Another area where we are seeing significant advances is gene editing, which is moving from concept to reality. New technologies within the space bring increased accuracy and precision, nudging us closer to finding a cure for a range of neurological and cardiac conditions as well as blood disorders such as sickle cell disease. In time, gene editing may be able to address any disease caused by mutations in a single gene, such as Duchenne muscular dystrophy, cystic fibrosis and Huntington’s disease.
Cell therapy is another key development we are monitoring. Cell therapies aim to harness living cells to combat cancer, address autoimmune conditions and produce missing proteins. Recent approvals of several chimeric antigen receptor (CAR) T-cell therapies represent major advances in the treatment of blood cancers.
Autoimmune diseases are caused by a malfunctioning immune system that attacks healthy tissues in the body. One example of a company innovating in this area is a biotech company specialising in antibody engineering in order to create new treatment options for patients afflicted with ulcerative colitis, an autoimmune disease affecting the large intestine.
Example is for illustrative purposes only and not intended as an investment recommendation.
The technologies and devices transforming treatment — Powerful innovation within medtech is revolutionising our ability to treat complex illnesses and conditions, as advances in hardware, software and bioinformatics combine to drive more effective treatments.
For example, robotic-assisted surgery penetration has grown as improvements in hardware and software have led to greater efficacy. Initially relegated to a few specialities in urology, robotic surgery is increasingly being used for multiple categories within general surgery that were historically performed via laparoscopy or open surgery, as the technology allows complex procedures to be performed with greater precision, flexibility and reproducibility. We anticipate data playing a bigger role, for example empowering health systems to leverage informatics to compare surgical KPIs and monitor surgeon quality. Future advances will further transform surgery, with a focus on areas such as improved pre-surgical visualisation and biopsies, enhancing both accuracy and access to treatment, as well as continued informatics.
Genetic sequencing technology has evolved significantly, developing brand new ecosystems both on the front end and back end of treatment algorithms; these technologies can both screen and diagnose genetic abnormalities earlier as well as treat later-stage disease with targeted therapeutics. The sector's leading companies have driven tremendous advances during the last 15 years, making a once laborious process faster and more streamlined. Hardware has also improved; DNA sequencing tools continue to evolve, with “third-generation” technologies able to detect more obscure genetic variants as well as drive down the cost curve of whole genome and exome sequencing costs. Genetic testing is essential for both diagnosing patients as well as deploying the most effective targeted therapeutic; once a mutation is identified, the patient can be matched to the most effective drug developed to target their individual disease. Bioinformatics tools and resources are further speeding up the process of developing, optimising and testing drugs (Figure 1) and we expect advances within AI to further assist with drug discovery, by quickly identifying more promising drug candidates and improving the speed of the entire process.
Figure 1
Within medical devices, there have been several large advances across a broad range of therapeutic categories. In cardiology, dramatic improvements in treating aortic stenosis offer far less invasive approaches, such as transcatheter aortic valve replacement (TAVR), and in the next decade we envisage this expanding to mitral valve disease. Traditionally, much of the focus for devices has been in the acute treatment space; however, we see significant opportunities where devices are combined with data, helping transform prevention and patient monitoring. A combination continuous-glucose monitor and insulin infusion pump offers the potential to improve patient outcomes in diabetes, allowing the pump to automatically deliver the right dose of insulin based on real-time sensor data and proprietary algorithms. This is the closest innovation yet to an artificial pancreas, allowing treatment without burdening the patient and significantly improving both efficacy as well as quality of life.
As one of the world's leading medtech providers, this company offers products across a range of areas, including orthopaedics, neurotechnology and medical and surgical equipment. The company is experiencing robust growth thanks to a number of new innovations and strong demand for patient procedures after COVID.
Example is for illustrative purposes only and not intended as an investment recommendation.
We believe these trends will benefit a variety of companies, including:
However, there are risks to the outlook, as with any investment theme. For example, ethical concerns surround gene therapy and gene editing, especially around the question of what constitutes a “faulty” gene. As an untested technology, gene editing is subject to numerous health concerns; while an edited gene may deliver short-term improvements to an individual, the long-term impact, or indeed any impacts to future populations, won’t be clear for many years. That said, we believe the market for innovative technologies and therapies is expanding at a rapid pace, and there is a significant opportunity for investors to identify promising beneficiaries poised to transform health care.
Stay up to date with the latest market insights and our point of view.
US election special: which investment themes win at the polls?
The upcoming US election could be one of the most momentous in recent history. How could the result affect different investment themes? Our thematic team investigate the potential implications for investors.
Thematic investing focus: how exactly will AI transform the world?
We are on the brink of a technological revolution that has major implications for all sectors, companies, labour, and regulators. How can a thematic lens help investors separate hype from reality?
Beyond the hype: finding AI’s long-term winners
Our expert argues that a long-term mindset based on deep research can help to uncover evolving AI investment opportunities amid the hype.
Thematic investing focus: evolving the current generation of energy
The energy transition is taking place amid a greater focus on energy security and affordability. What could this mean for the role of traditional energy companies, ask Keith White Daouii Abouchere and Megan Galligan.
Thematic investing focus: advancing the next generation of energy
The decarbonisation process represents the biggest capital cycle in our lifetime. As we develop the next generation of energy, Keith White, Daouii Abouchere and Megan Galligan examine how thematic investors can make the most of this structural opportunity.
Thematic investing focus: security in a world of great-power competition
In an environment of accelerating great-power competition and geopolitical instability, policymakers may place a higher emphasis on security – even at the expense of economic efficiency. What could this mean for thematic investors?
Multi-Asset Market Outlook
To help think through the asset allocation outlook and implications for 2023, we offer views from iStrat, our investment strategy and solutions group
Navigating a volatile reality: three ideas for 2024 and beyond
2023 saw investors grapple with a new, more volatile reality. How should portfolios be positioned for opportunities and challenges in 2024?
What route is right in emerging markets investing?
How can investors find the most compelling opportunities within emerging market equities? Simon Henry and Dáire Dunne explain why they think targeting the economic development opportunity may provide a roadmap for success.
Investing at the biopharma frontier
Rebecca Sykes details groundbreaking innovations happening today in the biopharmaceutical industry. She explains key advancements and the investment landscape for therapies targeting diabetes, cancer, and Alzheimer's disease, three of the deadliest and most expensive diseases facing the world today.
URL References
Related Insights
Trends and transformation distilled: Our 2024 outlook in brief
Our experts explore investment opportunities and risks for the year ahead.
Multiple authors